Alvotech Faces Investigation Over Misleading Information, Stock Plummets 34%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Source: Globenewswire
- Stock Price Plunge: Alvotech's stock plummeted 34% on November 3, 2025, following allegations of issuing misleading business information, with an additional nearly 4% drop the next day, severely undermining investor confidence.
- Legal Investigation Initiated: The Rosen Law Firm has announced an investigation into potential securities claims against Alvotech, aiming to seek compensation for affected shareholders, highlighting strong investor concerns regarding the company's transparency.
- FDA Response: In a statement on November 2, 2025, Alvotech revealed that the FDA issued a complete response letter for its Biologics License Application, citing deficiencies found during an inspection of its Reykjavik facility, which further exacerbated market anxiety.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing investors to participate without any out-of-pocket fees, indicating heightened market awareness of Alvotech's future legal risks and financial implications.
ALVO
$4.9+Infinity%1D
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 10.67 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.730
Low
8.00
Averages
10.67
High
14.00
Current: 4.730
Low
8.00
Averages
10.67
High
14.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
